A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives
Official title: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K39/39 (Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives) appears on 4,194 US grants and 7,244 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,194
- Published applications
- 7,244
- Assignees
- 2,529
- Inventors
- 11,419
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 6 | 0 |
| 1978 | 6 | 0 |
| 1979 | 8 | 0 |
| 1980 | 10 | 0 |
| 1981 | 6 | 0 |
| 1982 | 10 | 0 |
| 1983 | 5 | 0 |
| 1984 | 9 | 0 |
| 1985 | 5 | 0 |
| 1986 | 11 | 0 |
| 1987 | 4 | 0 |
| 1988 | 8 | 0 |
| 1989 | 15 | 0 |
| 1990 | 9 | 0 |
| 1991 | 17 | 0 |
| 1992 | 16 | 0 |
| 1993 | 15 | 0 |
| 1994 | 7 | 0 |
| 1995 | 14 | 0 |
| 1996 | 21 | 0 |
| 1997 | 30 | 0 |
| 1998 | 51 | 0 |
| 1999 | 67 | 0 |
| 2000 | 52 | 0 |
| 2001 | 51 | 35 |
| 2002 | 69 | 131 |
| 2003 | 53 | 179 |
| 2004 | 45 | 218 |
| 2005 | 35 | 182 |
| 2006 | 57 | 171 |
| 2007 | 49 | 150 |
| 2008 | 63 | 169 |
| 2009 | 71 | 177 |
| 2010 | 91 | 188 |
| 2011 | 83 | 229 |
| 2012 | 109 | 218 |
| 2013 | 85 | 233 |
| 2014 | 161 | 274 |
| 2015 | 176 | 296 |
| 2016 | 196 | 379 |
| 2017 | 241 | 339 |
| 2018 | 256 | 388 |
| 2019 | 255 | 441 |
| 2020 | 279 | 458 |
| 2021 | 305 | 448 |
| 2022 | 233 | 510 |
| 2023 | 238 | 482 |
| 2024 | 220 | 403 |
| 2025 | 220 | 328 |
| 2026 | 148 | 218 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Immune adjuvant and vaccine composition including the same29 Sep 2026US 12,746,284 B2Republic of Korea (Animal and Plant Quarantine Agency)
- Immunomodulatory and oncolytic minicells and methods of use22 Sep 2026US 12,741,010 B2Vaxiion Therapeutics, Inc.
- Preparation including vaccine adjuvant22 Sep 2026US 12,741,021 B2Sumitomo Dainippon Pharma Co., Ltd.
- Vaccines, vaccine priming, and antigen dose sparing22 Sep 2026US 12,741,022 B2Adjuvance Technologies, Inc.
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- Vaccine Compositions8 Oct 2026US 2026/0306607 A1Seqirus Inc.
- Combination Vaccine8 Oct 2026US 2026/0306615 A1Seqirus Inc.
Most cited
By later US patents
- Antigen-adjuvant compositions and methods1,024US 8,790,658 B2Sanofi Pasteur Limited · 2014
- Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity737US 4,554,101 ANew York Blood Center, Inc. · 1985
- Saponin adjuvant520US 5,057,540 ACambridge Biotech Corporation · 1991
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunostimulatory nucleic acid molecules461US 6,239,116 B1Coley Pharmaceutical Group, Inc. · 2001